DK1653844T3 - Prionspecifikke peptidreagenser - Google Patents

Prionspecifikke peptidreagenser

Info

Publication number
DK1653844T3
DK1653844T3 DK04781105.4T DK04781105T DK1653844T3 DK 1653844 T3 DK1653844 T3 DK 1653844T3 DK 04781105 T DK04781105 T DK 04781105T DK 1653844 T3 DK1653844 T3 DK 1653844T3
Authority
DK
Denmark
Prior art keywords
prion
specific peptide
peptide reagents
reagents
specific
Prior art date
Application number
DK04781105.4T
Other languages
English (en)
Inventor
Melissa D Michelitsch
Celine Hu
Roland N Zuckermann
Michael D Connolly
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of DK1653844T3 publication Critical patent/DK1653844T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
DK04781105.4T 2003-08-13 2004-08-13 Prionspecifikke peptidreagenser DK1653844T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US49496203P 2003-08-13 2003-08-13
US57036804P 2004-05-12 2004-05-12
US58650904P 2004-07-09 2004-07-09
PCT/US2004/026363 WO2005016127A2 (en) 2003-08-13 2004-08-13 Prion-specific peptide reagents

Publications (1)

Publication Number Publication Date
DK1653844T3 true DK1653844T3 (da) 2013-03-11

Family

ID=34198970

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04781105.4T DK1653844T3 (da) 2003-08-13 2004-08-13 Prionspecifikke peptidreagenser

Country Status (14)

Country Link
US (1) US7439041B2 (da)
EP (1) EP1653844B1 (da)
JP (3) JP4709149B2 (da)
KR (1) KR101166012B1 (da)
AU (2) AU2004264953B2 (da)
BR (1) BRPI0413495A (da)
CA (1) CA2535261C (da)
DK (1) DK1653844T3 (da)
ES (1) ES2398394T3 (da)
HK (1) HK1090275A1 (da)
IL (1) IL173480A0 (da)
MX (1) MXPA06001588A (da)
NZ (2) NZ545385A (da)
WO (1) WO2005016127A2 (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1395833B1 (en) * 2001-05-31 2013-02-27 Adlyfe, Inc. Misfolded protein sensor method
US20050026165A1 (en) * 2001-05-31 2005-02-03 Cindy Orser Detection of conformationally altered proteins and prions
US20060035242A1 (en) * 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
JP4709149B2 (ja) * 2003-08-13 2011-06-22 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド プリオン特異的ペプチド試薬
US20060057671A1 (en) * 2004-09-10 2006-03-16 Orser Cindy S Immobilized probes and methods of detecting conformationally altered prion proteins
WO2006076683A2 (en) * 2005-01-13 2006-07-20 Novartis Vaccines And Diagnostics Inc. Isolation and detection of pathogenic prions
AU2006204705C1 (en) * 2005-01-13 2012-07-05 Novartis Vaccines And Diagnostics, Inc. ELISA assays using prion-specific peptide reagents
EP1848830A4 (en) * 2005-01-13 2009-05-06 Novartis Vaccines & Diagnostic ISOLATION OF PATHOGENIC PRIONS
ATE528649T1 (de) * 2005-02-15 2011-10-15 Adlyfe Inc Verfahren zum nachweis falsch gefalteter proteine und prionen
KR101340559B1 (ko) * 2005-06-01 2013-12-11 암젠 리서치 (뮌헨) 게엠베하 항-인터루킨2 항체
NZ566020A (en) * 2005-09-09 2012-08-31 Novartis Ag Prion-specific peptoid reagents
GB0519198D0 (en) * 2005-09-20 2005-10-26 Univ Cambridge Tech Tse detection
WO2008013859A2 (en) * 2006-07-28 2008-01-31 Adlyfe, Inc. Peptide probes for diagnostics and therapeutics
JP2010523978A (ja) * 2007-04-04 2010-07-15 ノバルティス アーゲー プリオンｅｌｉｓａ
JP2010523977A (ja) * 2007-04-04 2010-07-15 ノバルティス アーゲー プリオンアッセイ
WO2009041902A1 (en) * 2007-09-25 2009-04-02 Loefgren Kajsa Prion protein derived cell penetrating peptides and their uses
US8709472B1 (en) * 2007-11-13 2014-04-29 Abbott Cardiovascular Systems Inc. Bioactive agent-loaded heart-targeting nanoparticles
CN102083450A (zh) * 2008-04-30 2011-06-01 诺华有限公司 致病性构象异构体的分析
EP2128618A1 (en) * 2008-05-30 2009-12-02 Prion Diagnostica S.r.l. A process for monitoring the presence of pathogenic agents in biological fluids by nanostructured materials
US20100129290A1 (en) * 2008-11-26 2010-05-27 I.S.T. Corporation Smart contrast agent and detection method for detecting transition metal ions
US10266585B2 (en) 2009-08-28 2019-04-23 The Board Of Regents Of The Univerity Of Texas System Methods of treating brain injury
AU2011315920B2 (en) 2010-10-15 2016-04-28 The Board Of Regents Of The University Of Texas System Antibodies that bind amyloid oligomers
EP3370518B1 (en) 2015-10-14 2023-08-23 X-Therma, Inc. Compositions and methods for reducing ice crystal formation
AU2017263706B2 (en) * 2016-05-10 2020-04-09 Lg Electronics Inc. Mobile robot and control method therefor
US11000571B2 (en) 2016-06-27 2021-05-11 Florida State University Research Foundation, Inc. Modified fragments from the octarepeat region of prion protein as hemin binders
WO2018053472A1 (en) * 2016-09-19 2018-03-22 University Of Houston System Compositions and methods of targeting cancer stem cells
JP2021004175A (ja) * 2017-09-04 2021-01-14 国立大学法人東北大学 コンフォメーション病治療用材料、及びその製造方法、並びにコンフォメーション病医薬のスクリーニング方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU675053B2 (en) 1991-12-03 1997-01-23 Proteus Molecular Design Limited Fragments of prion proteins
AU4376093A (en) 1992-05-15 1993-12-13 Instituto Nazionale Neurologico C. Besta Soluble prion polypeptides, and methods for detecting and purifying thereof
US5948763A (en) 1995-06-07 1999-09-07 New York University Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
DE69632056T2 (de) * 1995-09-14 2004-12-30 The Regents Of The University Of California, Oakland Für natives prp-sc spezifische antikörper
US5750361A (en) 1995-11-02 1998-05-12 The Regents Of The University Of California Formation and use of prion protein (PRP) complexes
NZ333518A (en) 1997-02-06 2001-06-29 Enfer Technology Ltd Immunological assay for spongiform encephalopathies (TSE)
EP0861900A1 (en) 1997-02-21 1998-09-02 Erziehungsdirektion Of The Canton Zurich Immunological detection of prions
DE19741607A1 (de) 1997-09-20 1999-03-25 Prionics Ag Synthetische Polypeptide zur Diagnose und Therapie von Prionerkrankungen
JP2002522009A (ja) * 1998-04-14 2002-07-23 スージェン・インコーポレーテッド Ｓｔｅ−２０関連蛋白質キナーゼ
US6211149B1 (en) 1998-08-03 2001-04-03 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors of formation of protease resistant prion protein
FI982480A0 (fi) 1998-11-17 1998-11-17 Wallac Oy Immunomääritys nisäkkäiden tarttuvan spongiomuotoisen aivotaudin määrittämiseksi
AU3474100A (en) 1999-01-25 2000-08-07 Minerva Biotechnologies Corporation Rapid and sensitive detection of aberrant protein aggregation in neurodegenerative diseases
JP2003521477A (ja) 1999-06-23 2003-07-15 カプリオン ファーマシューティカルズ インコーポレーティッド プリオン蛋白質ペプチドおよびその使用
AU780414B2 (en) 1999-07-27 2005-03-17 D-Gen Limited Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases
EP1216258A1 (en) * 1999-09-28 2002-06-26 Universität Zürich Factors having prion-binding activity in serum and plasma and agents to detect transmissible spongiform encephalopathitis
FR2801106B1 (fr) 1999-11-12 2007-10-05 Commissariat Energie Atomique Procede de diagnostic d'une esst provoquee par une souche d'atnc dans un echantillon biologique et son utilisation dans le diagnostic differentiel des differentes souches d'atnc
EP1272509A2 (en) 2000-04-05 2003-01-08 V.I. Technologies, Inc. Prion-binding peptidic ligands and methods of using same
AU2001255735A1 (en) * 2000-04-28 2001-11-12 Synuthane International, Inc. Double metal cyanide catalysts containing polyglycol ether complexing agents
WO2001097785A2 (en) 2000-06-20 2001-12-27 Caprion Pharmaceuticals Inc. Basic copolymers for the treatment of prion-related-disease
DK1712920T3 (da) 2000-07-07 2009-05-11 Merck Serono Sa Tidlig diagnose af konformationelle sygdomme
GB0103508D0 (en) * 2001-02-13 2001-03-28 Univ Dundee Screening method and agents
EP1395833B1 (en) 2001-05-31 2013-02-27 Adlyfe, Inc. Misfolded protein sensor method
EP1572894B1 (en) 2001-11-21 2016-04-13 New York University Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid beta, prion protein, amylin, alpha synuclein, or polyglutamine repeats for induction of an immune response thereto
IL162333A0 (en) 2001-12-10 2005-11-20 Applied Research Systems Peptides inhibiting prions
RU2309410C2 (ru) 2002-02-28 2007-10-27 Майкроусенс Байофейдж Лимитед Связывание патологических форм прионовых белков
CA2481437A1 (en) 2002-04-09 2003-10-16 The Scripps Research Institute Motif-grafted hybrid polypeptides and uses thereof
US20040208919A1 (en) * 2002-06-13 2004-10-21 Nicolau Yves C. Vaccination against prion diseases
DE10230141B4 (de) 2002-07-04 2004-07-15 Priontype Gmbh Verfahren und Kit zur Anreicherung und zum Nachweis von veränderten Prion-Proteinen (PrPSc)
EP1382971A1 (en) * 2002-07-17 2004-01-21 Pepscan Systems B.V. Detection of prion disease
US20060057636A1 (en) 2002-08-21 2006-03-16 Peter Heegaard Composite peptide compounds for diagnosis and treatment of diseases caused by prion proteins
US20040072236A1 (en) 2002-09-27 2004-04-15 Neil Cashman PrPSc -interacting molecules and uses thereof
EP1554305B1 (en) 2002-10-23 2007-03-28 Centre for Research and Technology Hellas/Institute of Agrobiotechnology Prion protein-binding peptide sequences
AU2002352042A1 (en) 2002-11-18 2004-06-15 Prionics Ag Method for the detection of prpsc
US7863411B2 (en) 2002-12-03 2011-01-04 Pathogen Removal and Diagnostics Technologies Inc. Prion protein ligands and methods of use
EP1457500A1 (en) 2003-03-14 2004-09-15 University of Zurich Soluble hybrid prion proteins and their use in the diagnosis, prevention and treatment of transmissible spongiform encephalophathies
DK1615992T3 (da) 2003-04-04 2013-12-09 Pathogen Removal & Diagnostic Technologies Inc Prionproteinbindende materialer og fremgangsmåder til anvendelse
CA2522483A1 (en) 2003-04-14 2004-10-28 Julia T. Lathrop Method for identifying ligands specific for structural isoforms of proteins
JP4709149B2 (ja) * 2003-08-13 2011-06-22 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド プリオン特異的ペプチド試薬
DE102004043782A1 (de) 2004-09-08 2006-03-09 Heinrich-Heine-Universität Düsseldorf Polypeptide und Verfahren zur spezifischen Bindung von Prionen
US20060057671A1 (en) * 2004-09-10 2006-03-16 Orser Cindy S Immobilized probes and methods of detecting conformationally altered prion proteins

Also Published As

Publication number Publication date
IL173480A0 (en) 2006-06-11
CA2535261A1 (en) 2005-02-24
EP1653844A4 (en) 2009-01-14
US20050118645A1 (en) 2005-06-02
US7439041B2 (en) 2008-10-21
ES2398394T3 (es) 2013-03-15
NZ580256A (en) 2011-07-29
KR20060066088A (ko) 2006-06-15
AU2009225337A1 (en) 2009-11-05
BRPI0413495A (pt) 2006-10-17
AU2004264953B2 (en) 2009-07-23
AU2009225337B2 (en) 2012-12-06
EP1653844A2 (en) 2006-05-10
WO2005016127A2 (en) 2005-02-24
WO2005016127A3 (en) 2006-12-21
JP2010158247A (ja) 2010-07-22
EP1653844B1 (en) 2012-12-12
MXPA06001588A (es) 2006-08-25
HK1090275A1 (en) 2006-12-22
AU2004264953A1 (en) 2005-02-24
JP4709149B2 (ja) 2011-06-22
NZ545385A (en) 2010-12-24
KR101166012B1 (ko) 2012-07-23
JP2013033060A (ja) 2013-02-14
JP2007502120A (ja) 2007-02-08
CA2535261C (en) 2015-11-24

Similar Documents

Publication Publication Date Title
DK1653844T3 (da) Prionspecifikke peptidreagenser
NO2014013I1 (no) Linaclotide
DE602004009744D1 (de) Reagenzbehälter
NO20055459D0 (no) Prosesser
DE602004020635D1 (de) Lanzetten betreffende verbesserungen
NO20044347L (no) Anti-alfavbeta6-antistoff
DE50300325D1 (de) Vaginalpflegezusammensetzung
DE602004011161D1 (de) Kraftfahrzeugschliessanlage
ATE418924T1 (de) Marknagel
DE602004003294D1 (de) Flügelendkantenverstellmechanismus
DE602004016325D1 (de) Diosignalbandes
DK1689775T3 (da) GAG-bindende proteiner
ATE462365T1 (de) Marknagel
DE602004030208D1 (de) Heizwassergerät
ATE375761T1 (de) Marknagel
FI20031741A (fi) Liukukäytävä
FR2862675B1 (fr) Defonceuse
DK1611126T3 (da) Chromenonindoler
NO20030752L (no) Bolgedempningsanordning
DK1625148T3 (da) Peptidkompleks
NO20054086D0 (no) Depigmenteringsmidler
ATA16232003A (de) Sortierer
NO20053512D0 (no) IL-8-liknende proteiner
NO20050436D0 (no) Beta-lagnedbrytende peptider
NO20032882D0 (no) Bölgekraftverk